

Original Article

Asian Pacific Journal of Tropical Medicine



journal homepage: www.apjtm.org

doi: 10.4103/1995-7645.275413

Impact Factor: 1.77

Human leukocyte antigen class- II DRB1 alleles and *Giardia lamblia* infection in children: A case-control study

Samar N. El–Beshbishi¹, Ayat A. ElBlihy¹, Raefa A. Atia¹, Ahmed Megahed², Fatma A. Auf³

¹Department of Medical Parasitology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

²Pediatric Gastroenterology and Hepatology Unit, Mansoura University Children's Hospital, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

³Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

ABSTRACT

Objective: To compare the genotype frequencies of HLA class-II DRB1 alleles in *Giardia (G.) lamblia*-infected children.

Methods: A total of 490 Egyptian children aged 2-16 years were subjected to microscopic stool examination to detect *G. lamblia* infection, and to exclude other intestinal pathogens. On the basis of their microscopic findings, a group of 80 children were chosen as giardiasis cases, another 80 children were confirmed as *Giardia* free control group by immunochromatographic test, and the remaining children were excluded. Both giardiasis and control groups were then subjected to blood examination to identify their genetic type of HLA-DRB1 alleles.

Results: HLA class- [] DRB1*03:01 and DRB1*13:01 alleles were significantly associated with *G. lamblia* infection (*P*<0.001 for each variable). On the other hand, HLA class- [] DRB1*04:02, DRB1*10:01, DRB1*14:01 and DRB1*15:01 alleles were significantly demonstrated in *Giardia* free children. However, other HLA-DRB1 alleles did not show any significant association with giardiasis.

Conclusions: HLA class- II DRB1*03, DRB1*13, DRB1*04, DRB1*10, DRB1*14 and DRB1*15 alleles may be involved in the establishment of host immune response to *G. lamblia* infection.

KEYWORDS: *Giardia lamblia*; Giardiasis; Human leukocyte antigen; HLA class-II DRB1 alleles; Children

1. Introduction

Giardia (G.) lamblia is one of the most prevalent intestinal protozoa

that infects humans worldwide, causing the disease giardiasis[1,2]. In Egypt, the estimated prevalence of giardiasis is 18%-48%[3,4]. The clinical features of *G. lamblia* infection vary from asymptomatic infection in about half of cases mainly in resource-poor settings, to loss of appetite, nausea, vomiting, abdominal pain, flatulence, diarrhea, dehydration and severe malabsorption syndrome[5].

The host defenses to eradicate *Giardia* infection are mediated through a synergism between both innate and adaptive immunity, but the exact defense mechanisms are still poorly understood[6]. CD4⁺ T cells have been identified to play a major role in control of *Giardia* infection, while the effector mechanisms involved in parasite elimination are obscure[7].

It is worth mentioning that the existence or absence of a specific human leukocyte antigen (HLA) class- [] allele and HLA polymorphism play a crucial role in individual variations in susceptibility and clinical variability of some parasitic diseases[8–11]. The role of HLA class- [] genes responsible for proper antigen recognition and presentation to CD4⁺ T cells in *G. lamblia* infection has not yet evaluated in human. Hence, this study was conducted to reveal the influence of HLA-DRB1 alleles on the susceptibility or resistance to *G. lamblia* infection in children.

^{III}To whom correspondence may be addressed. E-mail: selbeshbishi@gmail.com; selbeshbishi@mans.edu.eg; selbeshbishi@yahoo.com.

For reprints contact: reprints@medknow.com

©2020 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer-Medknow. All rights reserved.

How to cite this article: El-Beshbishi SN, ElBlihy AA, Atia RA, Megahed A, Auf FA. Human leukocyte antigen class- [] DRB1 alleles and *Giardia lamblia* infection in children: A case-control study. Asian Pac J Trop Med 2020; 13(2): 56-61.

Article history: Received 9 August 2019 Accepted 5 January 2020 Revision 31 December 2019 Available online 14 January 2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

2. Materials and methods

2.1. Ethical approval and informed consent

The study was approved by the Mansoura Faculty of Medicine Institutional Research Board (No. #R/17.04.100), and was conducted according to the human experimentation ethical guidelines of the Institution Medical Research Ethics committee and the Helsinki Declaration (as revised in 2000). Written informed consent was obtained from parents or legal guardians of the recruited children after explaining the aim of the study. All data of the enrolled children were kept strictly confidential. Patients were referred to a gastroenterologist for treatment of diarrhea and giardiasis.

2.2. Participants

A case control was conducted on a total of 490 Egyptian children aged 2-16 years of both sex attending Mansoura University Children's Hospital, Mansoura, Egypt. The criteria for inclusion were: detection of *Giardia* parasite by microscopic stool examination with or without clinical manifestations of giardiasis. The exclusion criteria were: presence of other intestinal parasitic, bacterial or viral infections, viral hepatitis, autoimmune diseases, and administration of systemic corticosteroids or immunosuppressive therapy. Additionally, all siblings were not recruited in the study, as they share 50% of their genetic alleles on average. Accordingly, a total of 80 giardiasis cases were enrolled and another 80 apparently healthy *Giardia* free children were recruited as control group.

2.3. Intervention

A pre-planned sheet format was filled for each child including relative demographic and clinical data as age, sex, residence and gastrointestinal manifestations. Three consecutive stool samples and 5 mL blood sample were collected from each participant and then transferred to the laboratory of Medical Parasitology and Clinical Pathology Departments, Faculty of Medicine, Mansoura University for identification of *G. lamblia* infection, and genotyping of HLA class II-DRB1 alleles, respectively.

2.4. Sample size

Sample size (SS) was statistically calculated according to the following equation: $SS=Z^{2*}(p)*(1-p)/D^2$. Where: Z=95% confidence level, p=prevalence reported by previous studies, d=5% margin of error.

SS=(95%)²*18%*(1-18%)/(5%)²=53

Convenient sample size of 490 children was examined to obtain 160 participants.

2.5. Stool sampling and testing for Giardia

Stool samples were collected from each participant in clean, wide

mouthed plastic containers with tight fitted lids, labeled with the patient's name, age, sex and date of collection, and then transferred on ice at -4 °C to the laboratory of Medical Parasitology. Samples were examined within one hour by direct wet mount (saline and iodine), and concentrated by formal ethyl acetate technique[12] to detect *G. lamblia* parasites. *Giardia* antigen immunochromatographic capture test (*Giardia*-Strip, CorisBioconcept, Belgium) was also used to confirm the absence of *Giardia* infection in case of negative stool specimens.

2.6. Identification of other enteric pathogens in stool

Besides testing for *Giardia* infection, all stool samples were examined for the presence of other intestinal parasitic, bacterial, and viral pathogens. Trichrome, modified trichrome[13], and modified Ziehl Neelsen staining[14], were used to exclude *Entamoeba histolytica*, *Microspora*, *Cryptosporidium*, *Cystoisospora*, as well as *Cyclospora* infections, respectively. Additionally, microbiological analysis of stool specimens included culture on *Salmonella– Shigella*, and MacConkey for isolation of *Salmonellae/Shigella* species, and *Escherichia coli*, respectively. Commercial ELISA assays (Ridascreen, R-biopharm, Germany) were used for detection of *Adenovirus* and *Rotavirus* antigens, according to manufacturer's instructions.

2.7. Blood samples and MHC class II typing

In this study, MHC class II typing was performed in all groups. For genetic analysis, genomic DNA was extracted from 200 µL of peripheral blood using TIANamp Genomic DNA (TIANGEN, China). HLA class II -DRB1 was typed using PCR and sequence-specific oligonucleotide probes according to manufacturer's instructions (INNO-LIPA HLA-DRB1, Innogenetics, Belgium).

2.8. Statistical analysis

Statistical package for social science software (Version 20, USA) was used for statistical analysis. The qualitative data were presented in the form of number and percentage and the *Chi*-square test was used to test the statistical significance. The quantitative data were presented as mean and standard deviation (mean±SD) and the Student's *t*-test was used as a test of significance. Alleles with frequencies $\leq 10\%$ were excluded from further analysis even if they showed significant correlations to minimize confusion with the least frequent alleles. Odds ratio (*OR*) and 95% confidence interval (*CI*) were calculated to estimate the risk of different alleles and the magnitude of association between HLA alleles and occurrence of *Giardia* infection. Significance was considered when *P* values were less than 0.05. *P* value was corrected by two-sided Monte Carlo (*P*^{MC}) significance (99% *CI*).

3. Results

To determine the genotype frequencies of HLA class- II DRB1 alleles in *G. lamblia*-infected children, this case-control study was conducted on two groups of children, giardiasis and control groups. On the basis of microscopic examinations of their stool samples, a total of 80 children with confirmed isolated *Giardia* infection were included as giardiasis group, another 80 children apparently healthy and free of *Giardia* infection by both microscopy and immunochromatographic capture test were enrolled as control group. The remaining children had either multiple parasitic infections (188 children) or other enteric pathogens (127 children) were excluded from the study as depicted in Figure 1.

Baseline demographic characteristics of the enrolled children and clinical manifestations of giardiasis are displayed in Table 1 and 2, respectively. Analysis of data revealed that the study groups were similar (P>0.05) in respect to sex and mean age. The majority of the recruited children were from villages; as 62.50% of cases as well as 50% of controls were rural residents, while the remaining were residing cities; illustrating a significant correlation (P=0.043) between residence in rural areas and the incidence of giardiasis (Table 1). Moreover, most of giardiasis cases did not show any clinical symptoms (50% of cases), meanwhile, the main gastrointestinal complaints of *Giardia* infection were abdominal pain (47.50%), diarrhea (23.75%), flatulence (20%), and vomiting (12.50%) as shown in Table 2.

3.1. HLA typing analysis

For genetic analysis, the HLA-DRB1 alleles of the enrolled children were analyzed to identify the allele/s with relative risk or protective effect to *G. lamblia* infection as depicted in Table 3 and 4. The HLA-DRB1 loci have a large number of allelic variants, with frequencies ranged from 0.00% to 34.37%. Interestingly, the HLA-

DRB1*03 allele was the most common allele shared in giardiasis cases representing 34.37% (55/160 alleles), nearly 14 times of the controls (2.50%; 4/160 alleles), with a statistically significant difference (OR=20.93; 95% CI: 6.80-68.70; P<0.001). The second most common allele detected with significant correlation with G. *lamblia* infection was HLA-DRB1*13, accounting for 16.25% of the revealed alleles (26/160 alleles; OR=3.20; 95% CI: 1.32-8.00; P=0.005). On the contrary, HLA-DRB1*04, DRB1*14, and DRB1*10 as well as DRB1*15 alleles showed higher rates within the control group (20%; 32/160 alleles, 15%; 24/160 alleles and 10%; 16/160 alleles, respectively) than among all giardiasis cases. Besides, HLA-DRB1*10 allele was only detected within the control group (P<0.001). The other HLA-DRB1alleles did not show any significant relationship with G. *lamblia* infection.

 Table 1. Demographic characteristics of *Giardia lamblia*-infected cases
 (giardiasis) and non-infected children (controls).

· ·			
Characteristics	Giardiasis	Controls	P-value
Male	46 (57.50)	32 (40.00)	>0.05
Female	34 (42.50)	48 (60.00)	
Urban residence	30 (37.50)	40 (50.00)	0.043
Rural residence	50 (62.50)	40 (50.00)	
Age	8.30±3.70	10.15±1.40	>0.05

Data presented are numbers and percentages of children, except for age (mean \pm SD). SD: standard deviation. Test of significance: *Chi*-Square test, except for age the Student's *t*-test was used.

Table 2. Cli	nical manife	estations of	giardiasis	cases
			0	

Clinical manifestations	No. (%)
Asymptomatic	40 (50.00)
Abdominal pain	38 (47.50)
Diarrhea	19 (23.75)
Flatulence	16 (20.00)
Vomiting	10 (12.50)
Mild to moderate dehydration	3 (3.75)
Low grade fever	3 (3.75)
Headache	21 (26.25)
Pallor	11 (13.75)

Data presented are numbers and percentages.



Figure 1. Number of giardiasis cases as well as normal Egyptian children recruited in the case-control study.

Table 3. Association of different HLA-DRB1 alleles with Giardia lamblia infection among infected cases and non-infected children (controls).

Infected cases $[n(\%)]$	Controls $[n (\%)]$	Odds ratio (95% CI)	Chi-square test
6 (3.75)	12 (7.50)	0.48 (0.16-1.42)	$X^2 = 2.12$
			$P^{\rm MC}$ =0.394 (0.381-0.406)
55 (34.37)	4 (2.50)	20.93 (6.8-68.7)	$X^2 = 54.40$
			P ^{MC} <0.001 (<0.001-<0.001)*
16 (10.00)	32 (20.00)	4.30 (0.22-0.86)	$X^2 = 6.27$
			P ^{MC} =0.047 (0.041-0.052)*
13 (8.12)	20 (12.50)	0.62 (0.28-1.36)	$X^2 = 2.26$
			P^{MC} =0.344 (0.331-0.356)
8 (5.00)	8 (5.00)	1.00 (0.17-7.49)	$X^2 = 8.42$
			$P^{\text{MC}}=0.016 \ (0.012-0.019)^*$
6 (3.75)	4 (2.50)	1.54 (0.38-6.64)	$X^2 = 0.41$
			$P^{\rm MC}$ =0.843 (0.833-0.852)
0 (0.00)	16 (10.00)	-	$X^2 = 16.80$
			P ^{MC} <0.001 (<0.001-0.001)*
16 (10.00)	12 (7.50)	1.37 (0.59-3.21)	$X^2 = 3.44$
			$P^{\rm MC}$ =0.190 (0.180-0.201)
3 (1.80)	0 (0.00)	-	$X^2 = 9.08$
			$P^{\text{MC}}=0.027 \ (0.022-0.031)^*$
26 (16.25)	8 (5.00)	3.20 (1.32-8.00)	$X^2 = 10.66$
			$P^{\text{MC}}=0.005 \ (0.003-0.007)^*$
6 (3.75)	24 (15.00)	0.29 (0.09-0.87)	X2=11.90
			$P^{\rm MC}$ =0.003 (0.002-0.005)*
5 (3.12)	16 (10.00)	0.27 (0.05-1.35)	$X^2 = 8.70$
			$P^{\rm MC}$ =0.013 (0.010-0.016)*
0 (0.00)	4 (2.50)	-	$X^2 = 4.05$
			P^{MC} =0.187 (0.176-0.197)
160 (100.00)	160 (100.00)	-	
	Infected cases [n (%)] 6 (3.75) 55 (34.37) 16 (10.00) 13 (8.12) 8 (5.00) 6 (3.75) 0 (0.00) 16 (10.00) 3 (1.80) 26 (16.25) 6 (3.75) 5 (3.12) 0 (0.00) 160 (100.00)	Infected cases $[n (\%)]$ Controls $[n (\%)]$ 6 (3.75)12 (7.50)55 (34.37)4 (2.50)16 (10.00)32 (20.00)13 (8.12)20 (12.50)8 (5.00)8 (5.00)6 (3.75)4 (2.50)0 (0.00)16 (10.00)16 (10.00)12 (7.50)3 (1.80)0 (0.00)26 (16.25)8 (5.00)6 (3.75)24 (15.00)5 (3.12)16 (10.00)0 (0.00)4 (2.50)	Infected cases $[n (\%)]$ Controls $[n (\%)]$ Odds ratio (95% CI)6 (3.75)12 (7.50)0.48 (0.16-1.42)55 (34.37)4 (2.50)20.93 (6.8-68.7)16 (10.00)32 (20.00)4.30 (0.22-0.86)13 (8.12)20 (12.50)0.62 (0.28-1.36)8 (5.00)8 (5.00)1.00 (0.17-7.49)6 (3.75)4 (2.50)1.54 (0.38-6.64)0 (0.00)16 (10.00)-16 (10.00)12 (7.50)1.37 (0.59-3.21)3 (1.80)0 (0.00)-26 (16.25)8 (5.00)3.20 (1.32-8.00)6 (3.75)24 (15.00)0.29 (0.09-0.87)5 (3.12)16 (10.00)-160 (100.00)160 (100.00)-

Data presented are numbers and percentages of HLA-DRB1 alleles. CI: confidence interval. *Statistical difference from controls. $P^{MC}=P$ value by two-sided Monte Carlo significance (99% CI).

Table 4. Estimated risk of alleles associated with pro	otection or susceptibility to	giardiasis among the studied gi	oups.
--	-------------------------------	---------------------------------	-------

HLA-DRB1 allele	Infected cases [n (%)]	Controls $[n (\%)]$	Odds ratio (95% CI)	Chi-square test
03:01	44 (27.50)	4 (2.50)	21 (6.54-74.80)	$X^2 = 42.353$
				P ^{MC} <0.001 (<0.001-0.001)*
13:01	15 (9.37)	0 (0.00)	2.33 (2.23-8.95)	$X^2 = 19.235$
				P ^{MC} <0.001 (<0.001-0.001)*
04:02	3 (1.87)	16 (10.00)	0.16 (0.03-0.60)	$X^2 = 10.463$
				$P^{\rm MC}$ =0.004 (0.002-0.006)*
10:01	0 (0.00)	16 (10.00)	-	$X^2 = 16.800$
				P ^{MC} <0.001 (<0.001-0.001)*
14:01	6 (3.75)	24 (15.00)	0.19 (0.04-0.79)	$X^2 = 11.917$
				P^{MC} =0.003 (0.001-0.004)*
15:01	3 (1.87)	16 (10.00)	0.12 (0.02-0.52)	$X^2 = 10.463$
				$P^{\text{MC}}=0.004 \ (0.002-0.006)^*$

Data presented are numbers and percentages of HLA-DRB1alleles. CI: confidence interval. *Statistical difference from controls. $P^{MC}=P$ value by two-sided Monte Carlo significance (99% CI).

3.2. Estimated risk of susceptibility and protective HLA– DRB1 alleles in the cohorts

Out of the 55 HLA-DRB1*03 alleles, HLA-DRB1*03:01 allele was the most frequent susceptibility allele (44 alleles) among children infected with *G. lamblia*, with significant difference between cases and controls (*OR*=21; 95% *CI*: 6.54-74.80; *P*<0.001). Interestingly, HLA-DRB1*03:01/03:02 allotype was the most frequent HLA-allotype detected in children with giardiasis clinical presentations (15%; 6/40 alleles), while children with asymptomatic infection were not likely to carry this allotype (0%; 0/40 alleles),

revealing a significant correlation (x^2 = 6.49, *P*=0.01) to giardiasis manifestations (unpublished data). Additionally, among the different HLA-DRB1*13 alleles, HLA-DRB1*13:01 allele was the most common allele detected in *Giardia*-infected children (15 alleles), with significant difference between cases and controls (*OR*=2.33; 95% *CI*: 2.23-8.95; *P*<0.001). Moreover, this allele was not observed among the control children. On the other hand, HLA-DRB1*04:02 as well as DRB1*15:01, DRB1*10:01 and DRB1*14:01 variants were the most common alleles with negative correlation with *G. lamblia* infection (*P*=0.004, *P*=0.004, *P*<0.001 and *P*=0.003, respectively) as shown in Table 4.

4. Discussion

Giardiasis results in a considerable burden of illness, although manifestations of infection differ among people, ranging from acute to chronic disease, some hosts are symptomless^[15]. In accordance with previous studies^[16,17], the current work revealed that 50% of *G. lamblia* infections are asymptomatic. Additionally, the study result is in agreement with that of Naz *et al.*^[18], which revealed the highest rate of *Giardia* infections in rural residents.

Previous studies highlighted that variation in giardiasis manifestations is referred to different factors, including host immune response[6,19], however; the exact role of the host immune status against *G. lamblia* infection still needs an illustration. In the last years, many researches have correlated HLA polymorphism with the susceptibility and clinical variability of major parasitic diseases[20–23]. As most of HLA class- II processing occurs in the antigen-presenting cells as B cells, macrophages and dendritic cells[24], and a single allele is equipped for presenting distinct thousand peptides to a CD4⁺ T cell[25]. Therefore, it is logic that the presence or absence of a specific HLA class- II allele could modify the response to an infective organism by altering the proteins presented to CD4⁺ T cells.

The HLA class- II molecules are encoded by three different regions of the major histocompatibility complex (MHC-DR, -DQ, and -DP), where HLA-DR sub-region is the most complex of the entire HLA-D region[8]. The most paramount finding of the current study is the proof that HLA class- II DRB1 allele polymorphism is undeniable factor that influences the susceptibility to *G. lamblia* infection. Egyptian children infected with *G. lamblia* were more likely to carry the HLA class- II DRB1*03 or *13 alleles, and DRB1*03:01 & *13:01 were the most frequently associated alleles; suggesting that these alleles may have a role in susceptibility to giardiasis. However, further research is needed to evaluate the role of HLA class- II DRB1*03 and *13 alleles in antigen recognition and/ or presentation to CD4⁺ T cells, HLA- CD4⁺ T cells interaction and cytokines production.

The study also revealed a negative association between the HLA class- II DRB1*04, *10, *14 and *15 alleles and the development of *G. lamblia* infection. Besides, the HLA-DRB1*04:02, as well as *10:01, *14:01, and *15:01 were the most mutual alleles among control children. Accordingly, these alleles could participate in protective immune response to human *G. lamblia* infection through effective antigen processing and presentation to the CD4⁺ T-cell receptor, however; the exact underlying mechanism requires further evaluation.

Our work supports the concept that HLA class- II molecules are associated with host protection or susceptibility to distinct parasitic infections[26]. Previous studies on other enteric protozoal infections demonstrated an association of the HLA haplotype DQB1*06:01/DRB1*15:01 with a delay in *Entamoeba histolytica* infection onset[25]. Also, significant associations of asymptomatic cryptosporidiosis with the HLA class- II DQB1*03:01, and DQB1*03:01/DRB1*11:01 haplotype with both asymptomatic and symptomatic infections in children have been recorded[27]. Several studies have also reported associations of HLA class-II alleles with resistance or susceptibility and courses of major parasitic diseases, as: class II HLA-DRB1*1302/DQB1*0501 haplotype with mild form of falciparum malaria in Gambian patients[28], HLA-DRB1*04 allele with severe malaria in North Ghana[22], as well as HLA-DRB1*13/14 and DRB1*15/16 as risk and protective alleles, respectively, for visceral leishmaniasis[23]. Moreover, a debatable role for position 11 of the HLA class II -DP alpha chain in the consequence of schistosomiasis haematobium has been demonstrated[20].

The results of the current study also corroborate with other studies that correlated the development of different clinical diseases to HLA-DRB1 variations among Egyptian population. Azab et al.[21] reported a statistically significant positive association between HLA-DRB1*3 and the occurrence of cystic echinococcosis, where patients with DRB1*3 were found to be more susceptible to complications. Moreover, studies conducted on patients with hepatic diseases detected the HLA-DRB1*03 allele in about 45.6% of children afflicted with hepatitis C virus (HCV)[29]. Interestingly, class II DRB1*03 allele has also been identified in 25.29% of adults with chronic HCV[30], an allele similar to the one detected in our study, suggesting that there may be a common gene influencing susceptibility to giardiasis, cystic echinococcosis, and HCV infection among Egyptians. Besides, the DRB1*13 was the most common allele (26.07% and 36%) found in patients with chronic HCV and children with autoimmune hepatitis (AIH)[30,31], respectively, compared to 16.25% (second most common allele) in our giardiasis cases. Results reflecting that DRB1*13 may also act as a risk allele for AIH, HCV persistence and giardiasis in Egyptian population.

Our study is only a case-control study, and there is a prospect of confusion from other obscure or unmeasured parameters. There is also a potential for selection bias, as only 160 children out of 490 were recruited in the study. Also, this is a non-funded study, so the high cost of HLA and cytokines kits was a restricting factor for conducting a multicenter study, genotyping other alleles and assessing some immune-regulatory cytokines as IL-17, IL-6, and TNF- α , since HLA class-II alleles might bias toward or away from specific cytokine response against *Giardia* parasite.

In conclusion, this study throws some light on human HLA class-II DRB1 alleles differences in *G. lamblia* infection. Yet, thorough understanding of the influence of these alleles on immune response and clinical outcomes in giardiasis necessitates larger studies on different populations with in-depth analysis of genetic variations and immune responses interactions incorporated with epidemiological data.

Conflict of interest statement

We declare that we have no conflict of interest.

Authors' contributions

SNE conceived and designed the study protocol. AAE and AM collected the study cases and questionnaire them. AM conducted the pediatric clinical examination and treated the infected cases. AAE performed all the laboratory tests, and FAA helped in the genotyping. AAE and FAA analyzed data and interpreted results. SNE, RAA, and AM supervised the laboratory work and data analysis. ALL authors participated in drafting the article, SNE and AAE wrote the final form. The authors revised the manuscript critically for important intellectual contents, and approved it. And each author believes that the manuscript represents honest work.

References

- Ismail MA, El-Akkad DM, Rizk EM, El-Askary HM, El-Badry AA. Molecular seasonality of *Giardia lamblia* in a cohort of Egyptian children: A circannual pattern. *Parasitol Res* 2016; **115**(11): 4221-4227.
- [2] Escobedo AA, Almirall P, González-Fraile E, Ballesteros J. Efficacy of mebendazole in pediatric patients with giardiasis: A systematic review and meta-analysis. *Acta Trop* 2018; **188**: 50-57.
- [3] Elswaifi SF, Palmieri JR, El-Tantawy N, El-Hussiny M, Besheer T, Abohashe, E. Comparison of microscopic and immunoassay examination in the diagnosis of intestinal protozoa of humans in Mansoura, Egypt. J Parasit Dis 2017; 40(3): 580-585.
- [4] Fahmy HM, El-Serougi AO, ElDeeb HK, Hussein HM, Abou-Seri HM, Klotz C, et al. *Giardia duodenalis* assemblages in Egyptian children with diarrhea. *Eur J Clin Microbiol Infect Dis* 2015; **34**(8): 1573-1581.
- [5] Fletcher SM, Stark D, Harkness J, Ellis J. Enteric protozoa in the developed world: A public health perspective. *Clin Microbiol Rev* 2012; 25(3): 420-449.
- [6] Solaymani-Mohammadi SH, Singer SM. *Giardia duodenalis*: The doubleedged sword of immune responses in giardiasis. *Exp Parasitol* 2010; 126(3): 292-297.
- [7] Singer SM. Control of giardiasis by interleukin-17 in humans and miceare the questions all answered? *Clin Vaccine Immunol* 2016; 23(1): 2-5.
- [8] Horton R, Wilming LR, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, et al. Gene map of the extended human MHC. *Nat Rev Genet* 2004; 5(12): 889-899.
- [9] Huy NT, Hamada M, Kikuchi M, Lan NTP, Yasunami M, Zamora J, et al. Association of HLA and post-schistosomal hepatic disorder: A systematic review and meta-analysis. *Parasitol Int* 2011; 60(4): 347-356.
- [10]Mangano VD, Modiano D. Host genetics and parasitic infections. *Clin Microbiol Infect* 2018; 20: 1265-1275.
- [11]Shimokawa PT, Targa LS, Yamamoto L, Rodrigues JC, Kanunfre KA, Okay TS. HLA-DQA1/B1 alleles as putative susceptibility markers in congenital toxoplasmosis. *Virulence* 2016; 7(4): 456-464.
- [12]Truant AL, Elliott SH, Kelly MT, Smith JH. Comparison of formalinethyl ether sedimentation, formalin-ethyl acetate sedimentation, and zinc sulfate flotation techniques for detection of intestinal parasites. *J Clin Microbiol* 1981; 13(5): 882-884.
- [13]Ryan NJ, Sutherland G, Coughlan K, Globan M, Doultree J, Marshall J, et al. A new trichrome-blue stain for detection of microsporidial species in urine, stool, and nasopharyngeal specimens. *J Clin Microbiol* 1993; 31(12): 3264-3269.
- [14]Casemore DP, Armstrong M, Sands RL. Laboratory diagnosis of

cryptosporidiosis. J Clin Pathol 1985; 38(12): 1337-1341.

- [15]Cotton JA, Beatty JK, Buret AG. Host-parasite interactions and pathophysiology in *Giardia* infections. *Int J Parasitol* 2011; **41**(9): 925-933.
- [16]Nikoli A, Klun I, Bobi B, Ivovi V, Vujani M, Živković T, et al. Human giardiasis in Serbia: asymptomatic vs symptomatic infection. *Parasite* 2011: 18(2): 197-201.
- [17]Waldram A, Vivancos R, Hartley C, Lamden K. Prevalence of *Giardia* infection in households of *Giardia* cases and risk factors for household transmission. *BMC Infect Dis* 2017; **17**(1): 486.
- [18]Naz A, Nawaz Z, Rasool MH, Zahoor MA. Cross-sectional epidemiological investigations of *Giardia lamblia* in children in Pakistan. *Sao Paulo Med J* 2018; **136**(5): 449-453.
- [19]Cotton JA, Amat CB, Buret AG. Disruptions of host immunity and inflammation by *Giardia duodenalis*: Potential consequences for co-Infections in the gastro-intestinal tract. *Pathogens* 2015; 4: 764-792.
- [20]May J, Kremsner PG, Milovanovic D, Schnittger L, Loliger CC, Bienzle U, et al. HLA-DP control of human *Schistosoma haematobium* infection. *Am J Trop Med Hyg* 1998; **59**: 302-306.
- [21]Azab ME, Bishara SA, Ramzy RM, Oteifa NM, El-Hoseiny LM, Ahmed MA. The evaluation of HLA-DRB1 antigens as susceptibility markers for unilocular cystic echinococcosis in Egyptian patients. *Parasitol Res* 2004; 72(6): 473-477.
- [22]Osafo-Addo AD, Koram KA, Oduro AR, Wilson M, Hodgson A, Rogers WO. HLA-DRB1*04 allele is associated with severe malaria in northern Ghana. Am J Trop Med Hyg 2008; 78(2): 251-255.
- [23]Singh T, Fakiola M, Oommen J, Chakravarty J, Sundar S, Blackwell J. HLA Class II association with visceral leishmaniasis: The road to identifying vaccine candidates. Poster session presented at: 16th International Congress on Infectious Diseases; 2-5 April 2014; Cape Town.
- [24]Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin B. Expression of MHC II genes. In Singh H, Grosschedl R, editors. *Molecular analysis* of *B lymphocyte development and activation*. Germany: Springer-Verlag Berlin Heidelberg; 2005, p. 147-170.
- [25]Duggal P, Haque R, Roy S, Mondal D, Sack RB, Farr BM, et al. Influence of human leukocyte antigen class II alleles on susceptibility to *Entamoeba histolytica* infection in Bangladeshi children. *J Infect Dis* 2004; **189**(3): 520-526.
- [26]Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev 2009; 22(2): 370-385.
- [27]Kirkpatrick BD, Haque R, Duggal P, Mondal D, Larsson, C, Peterson K, et al. Association between *Cryptosporidium* infection and human leukocyte antigen class I and class II alleles. *J Infect Dis* 2008; **197**(3): 474-478.
- [28]Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common west African HLA antigens are associated with protection from severe malaria. *Nature* 1991; **352**: 595-600.
- [29]Yosry A, Fouad R, Mahmoud S, El-Raziky MS, El-Hennawy A, Ghoneim MA. The association of HLA class II DR B1 alleles with HCV infection in Egyptian children. *Arab J Gastroenterol* 2011; **12**(1): 25-28.
- [30]El-Bendary M, Neamatallah M, Elalfy H, Besheer T, Kamel E, Mousa HS, et al. HLA class II-DRB 1 alleles with hepatitis C virus infection outcome in Egypt: A multicentre family-based study. *Ann Hepatol* 2019; 18(1): 68-77.
- [31]Elfaramawy AA, Elhossiny RM, Abbas AA, Aziz HM. HLA-DRB1 as a risk factor in children with autoimmune hepatitis and its relation to hepatitis A infection. *Ital J Pediatr* 2010; 36: 73.